Flitcroft DI, He M, Jonas JB, et al. IMI - defining and classifying myopia: a proposed set of standards for clinical and epidemiologic studies. Invest Ophthalmol Vis Sci, 2019, 60(3): M20-M30. DOI: 10.1167/iovs.18-25957.
[2]
Wildsoet CF, Chia A, Cho P, et al. IMI - interventions myopia institute: interventions for controlling myopia onset and progression report. Invest Ophthalmol Vis Sci, 2019, 60(3): M106-M131. DOI: 10.1167/iovs.18-25958.
[3]
Morgan IG, French AN, Ashby RS, et al. The epidemics of myopia: aetiology and prevention. Prog Retin Eye Res, 2018, 62:134-149. DOI: 10.1016/j.preteyeres.2017.09.004.
[4]
Morgan IG, Wu PC, Ostrin LA, et al. IMI risk factors for myopia. Invest Ophthalmol Vis Sci, 2021, 62(5): 3. DOI: 10.1167/iovs.62.5.3.
[5]
Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology, 2016, 123(5):1036-1042. DOI: 10.1016/ j.ophtha.2016.01.006.
[6]
Bullimore MA, Brennan NA. Myopia control: why each diopter matters. Optom Vis Sci, 2019, 96(6):463-465. DOI: 10.1097/ OPX.0000000000001367.
[7]
Tideman JW, Snabel MC, Tedja MS, et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. JAMA Ophthalmol, 2016, 134(12): 1355-1363. DOI: 10.1001/jamaophthalmol.2016.4009.
[8]
Haarman AEG, Enthoven CA, Tideman JWL, et al. The complications of myopia: a review and meta-analysis. Invest Ophthalmol Vis Sci, 2020, 61(4): 49. DOI: 10.1167/iovs.61.4.49. Walline JJ, Lindsley KB, Vedula SS, et al. Interventions to slow
[9]
progression of myopia in children. Cochrane Database Syst Rev, 2020, 1 : CD004916. DOI: 10.1002/14651858.CD004916.pub4.
[10]
Organization WH. The impact of myopia and high myopia: report of the Joint World Health Organization-Brien Holden Vision Institute Global Scientific Meeting on Myopia. Geneva: World Health Organization, 2017.
[11]
Takashima T, Yokoyama T, Futagami S, et al. The quality of life in patients with pathologic myopia. Jpn J Ophthalmol, 2001, 45(1): 84-92. DOI: 10.1016/s0021-5155(00)00305-1.
[12]
Yokoi T, Moriyama M, Hayashi K, et al. Predictive factors for comorbid psychiatric disorders and their impact on visionrelated quality of life in patients with high myopia. Int Ophthalmol, 2014, 34(2): 171-183. DOI: 10.1007/s10792-013- 9805-8.
[13]
Naidoo KS, Fricke TR, Frick KD, et al. Potential lost productivity resulting from the global burden of myopia: systematic review, meta-analysis, and modeling. Ophthalmology, 2019, 126(3): 338-346. DOI: 10.1016/j.ophtha.2018.10.029.
Gifford KL, Richdale K, Kang P, et al. IMI - clinical management guidelines report. Invest Ophthalmol Vis Sci, 2019, 60(3): M184-M203. DOI: 10.1167/iovs.18-25977.
[16]
Xu L, Ma Y, Yuan J, et al. COVID-19 quarantine reveals that behavioral changes have an effect on myopia progression. Ophthalmology, 2021, 128(11): 1652-1654. DOI: 10.1016/ j.ophtha.2021.04.001.
[17]
Enthoven CA, Tideman J, Polling JR, et al. Interaction between lifestyle and genetic susceptibility in myopia: the Generation R study. Eur J Epidemiol, 2019, 4(8): 777-784. DOI: 10.1007/ s10654-019-00512-7.
[18]
Tedja MS, Haarman AEG, Meester-Smoor MA, et al. IMI - myopia genetics report. Invest Ophthalmol Vis Sci, 2019, 60(3): M89-M105. DOI: 10.1167/iovs.18-25965.
[19]
Zadnik K, Sinnott LT, Cotter SA, et al. Prediction of juvenileonset myopia. JAMA Ophthalmol, 2015, 133(6): 683-689. DOI: 10.1001/jamaophthalmol.2015.0471.
[20]
Mutti DO, Mitchell GL, Jones-Jordan LA, et al. The response AC/A ratio before and after the onset of myopia. Invest Ophthalmol Vis Sci, 2017, 58(3): 1594-1602. DOI: 10.1167/ iovs.16-19093.
[21]
Chen Y, Drobe B, Zhang C, et al. Accommodation is unrelated to myopia progression in Chinese myopic children. Sci Rep,2020, 10(1):12056. DOI: 10.1038/s41598-020-68859-6.
[22]
Logan NS, Radhakrishnan H, Cruickshank FE, et al. IMI accommodation and binocular vision in myopia development and progression. Invest Ophthalmol Vis Sci, 2021, 62(5): 4. DOI: org/10.1167/iovs.62.5.4
[23]
Sankaridurg PR, Holden BA. Practical applications to modify and control the development of ametropia. Eye (Lond), 2014, 28(2): 134-141. DOI: 10.1038/eye.2013.255.
[24]
Donovan L, Sankaridurg P, Ho A, et al. Myopia progression rates in urban children wearing single-vision spectacles. Optom Vis Sci, 2012, 89(1): 27-32. DOI: 10.1097/OPX.0b013e3182357f79.
[25]
Chua SY, Sabanayagam C, Cheung YB, et al. Age of onset of myopia predicts risk of high myopia in later childhood in myopic Singapore children. Ophthalmic Physiol Opt, 2016, 36(4): 388-394. DOI: 10.1111/opo.12305.
[26]
Nixon A, Brennan N. Managing Myopia: a Clinical Response to the Growing Epidemic. Online: 2020.
[27]
J S, JJ K, B B. Kanski's clinical ophthalmology: a systematic approach. 9 ed. Oxford: Oxford University Press, 2020:956.
[28]
Wu PC, Chen CT, Chang LC, et al. Increased time outdoors is followed by reversal of the long-term trend to reduced visual acuity in Taiwan primary school students. Ophthalmology, 2020, 127(11): 1462-1469. DOI: 10.1016/j.ophtha.2020.01.054.
[29]
Wu PC, Chen CT, Lin KK, et al. Myopia prevention and outdoor light intensity in a school-based cluster randomized trial. Ophthalmology, 2018, 125(8): 1239-1250. DOI: 10.1016/ j.optha.2017.12.01.
[30]
Xiong S, Sankaridurg P, Naduvilath T, et al. Time spent in outdoor activities in relation to myopia prevention and control: a meta-analysis and systematic review. Acta Ophthalmol, 2017, 95(6): 551-566. DOI: 10.1111/aos.13403.
[31]
French AN, Morgan IG, Mitchell P, et al. Risk factors for incident myopia in Australian schoolchildren: the Sydney adolescent vascular and eye study. Ophthalmology, 2013, 120(10): 2100-2108. DOI: 10.1016/j.ophtha.2013.02.035.
[32]
Huang HM, Chang DS, Wu PC. The Association between Near Work Activities and Myopia in Children-A Systematic Review and Meta-Analysis. PLoS One, 2015, 10(10): e0140419. DOI: 10.1371/journal.pone.0140419.
[33]
Chung K, Mohidin N, O'Leary DJ. Undercorrection of myopia enhances rather than inhibits myopia progression. Vision Res, 2002, 42(22): 2555-2559. DOI: 10.1016/s0042-6989(02)00258-4.
[34]
Sun YY, Li SM, Li SY, et al. Effect of uncorrection versus full correction on myopia progression in 12-year-old children. Graefes Arch Clin Exp Ophthalmol, 2017, 255(1): 189-195. DOI: 10.1007/s00417-016-3529-1.
[35]
Kinoshita N, Konno Y, Hamada N, et al. Additive effects of orthokeratology and atropine 0.01% ophthalmic solution in slowing axial elongation in children with myopia: first year results. Jpn J Ophthalmol, 2018, 62(5): 544-553. DOI: 10.1007/ s10384-018-0608-3.
[36]
Sankaridurg P, Donovan L, Varnas S, et al. Spectacle lenses designed to reduce progression of myopia: 12-month results. Optom Vis Sci, 2010, 87(9): 631-641. DOI: 10.1097/OPX.0b013e3181ea19c7.
[37]
Cheng D, Woo GC, Drobe B, et al. Effect of bifocal and prismatic bifocal spectacles on myopia progression in children: three-year results of a randomized clinical trial. MA Ophthalmol, 2014, 132(3): 258-264. DOI: 10.1001/ jamaophthalmol.2013.7623.
Bao J, Huang Y, Li X, ed al. Spectacle lenses with aspherical lenslets for myopia control vs single-vision spectacle lenses: a Randomized Clinical Trial. JAMA Ophthalmol, 2022 Mar 31. DOI: 10.1001/jamaophthalmol.2022.0401.
[40]
Chamberlain P, Peixoto-de-Matos SC, Logan NS, et al. A 3-year randomized clinical trial of MiSight lenses for myopia control. Optom Vis Sci, 2019, 96(8): 556-567. DOI: 10.1097/ OPX.0000000000001410.
[41]
Walline JJ, Walker MK, Mutti DO, et al. Effect of high add power, medium add power, or single-vision contact lenses on myopia progression in children: the BLINK randomized clinical trial. JAMA, 2020, 324(6): 571-580. DOI: 10.1001/ jama.2020.10834.
[42]
Sankaridurg P, Bakaraju RC, Naduvilath T, et al. Myopia control with novel central and peripheral plus contact lenses and extended depth of focus contact lenses: 2 year results from a randomised clinical trial. Ophthalmic Physiol Opt, 2019, 39(4): 294-307. DOI: 10.1111/opo.12621.
[43]
Lam CS, Tang WC, Tse DY, et al. Defocus incorporated soft contact (DISC) lens slows myopia progression in Hong Kong Chinese schoolchildren: a 2-year randomised clinical trial. Br J Ophthalmol, 2014, 98(1): 40-45. DOI: 10.1136/ bjophthalmol-2013-303914.
[44]
Yam JC, Jiang Y, Tang SM, et al. Low-concentration atropine for myopia progression (LAMP) study: a randomized, doubleblinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology, 2019, 126(1): 113-124. DOI: 10.1016/j.ophtha.2018.05.029.
[45]
Yam JC, Li FF, Zhang X, et al. Two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study: phase 2 report. Ophthalmology, 2020, 127(7): 910-919. DOI: 10.1016/j.ophtha.2019.12.011.
[46]
Lam CS, Tang WC, Lee PH, et al. Myopia control effect of defocus incorporated multiple segments (DIMS) spectacle lens in Chinese children: results of a 3-year follow-up study. Br J Ophthalmol, 2021 bjophthalmol-2020-317664. DOI: 10.1136/ bjophthalmol-2020-317664.
[47]
Chamberlain P, Bradley A, Arumugam B, et al. Long-term effect of dual-focus contact lenses on myopia progression in children: a 6-year multicenter clinical trial. Optom Vis Sci, 2022, 99(3): 204-212. DOI: 10.1097/OPX.0000000000001873.
[48]
Chia A, Lu QS, Tan D. Five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eyedrops. Ophthalmology, 2016, 123(2): 391-399. DOI: 10.1016/j.ophtha.2015.07.004.
[49]
Yam JC, Zhang XJ, Zhang Y, et al. Three-year clinical trial of low-concentration atropine for myopia progression (LAMP) study: continued versus washout: phase 3 report. Ophthalmology, 2022, 129(3): 308-321. DOI: 10.1016/ j.ophtha.2021.10.002.
[50]
Cho P, Tan Q. Myopia and orthokeratology for myopia control. Clin Exp Optom, 2019, 102(4): 364-377. DOI:10.1111/ cxo.12839.
[51]
Jong M, Jonas JB, Wolffsohn JS, et al. IMI 2021 yearly digest. Invest Ophthalmol Vis Sci, 2021, 62(5): 7. DOI: 10.1167/ iovs.62.5.7.
[52]
Stapleton F, Keay L, Edwards K, et al. The incidence of contact lens-related microbial keratitis in Australia. Ophthalmology, 2008, 115(10): 1655-1662. DOI: 10.1016/j.ophtha.2008.04.002.
[53]
Bullimore MA, Sinnott LT, Jones-Jordan LA. The risk of microbial keratitis with overnight corneal reshaping lenses. Optom Vis Sci, 2013, 90(9): 937-944. DOI: 10.1097/ OPX.0b013e31829cac92.
[54]
Bullimore MA. The safety of soft contact lenses in children. Optom Vis Sci, 2017, 94(6): 638-646. DOI: 10.1097/ OPX.0000000000001078.
[55]
Chia A, Chua WH, Cheung YB, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology, 2012, 119(2): 347-354. DOI: 10.1016/ j.ophtha.2011.07.031.